References
- Abbas, N., Hasan, S. S., Curley, L., & Babar, Z.-U.-D. (2020). Access to medicines—a systematic review of the literature. Research in Social & Administrative Pharmacy: RSAP, 16(9), 1166–1176. https://doi.org/https://doi.org/10.1016/j.sapharm.2019.12.009
- Alexa Internet. (n.d.). reddit.com competitive analysis, marketing mix and traffic—Alexa. https://www.alexa.com/siteinfo/reddit.com#section_traffic.
- Altheide, D. L., & Schneider, C. J. (2013). Qualitative media analysis. SAGE.
- Bartley, T., & Child, C. (2014). Shaming the corporation: The social production of targets and the anti-sweatshop movement. American Sociological Review, 79(4), 653. https://doi.org/https://doi.org/10.1177/0003122414540653
- Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., Hohmann, E., Chu, H. Y., Luetkemeyer, A., Kline, S., Lopez de Castilla, D., Finberg, R. W., Dierberg, K., Tapson, V., Hsieh, L., Patterson, T. F., Paredes, R., Sweeney, D. A., Short, W. R., … Lane, H. C. (2020). Remdesivir for the treatment of covid-19—preliminary report. The New England Journal of Medicine. https://doi.org/https://doi.org/10.1056/NEJMoa2007764
- Benton, J. (2020, February 10). The wall street journal joins The New York Times in the 2 Million digital subscriber club. Nieman Lab. https://www.niemanlab.org/2020/02/the-wall-street-journal-joins-the-new-york-times-in-the-2-million-digital-subscriber-club/.
- Brimeyer, T., Silva, E. O., & Byrne, R. J. (2016). What do unions do? Media framing of the two-faces of labor. WorkingUSA, 19(4), 517–532. https://doi.org/https://doi.org/10.1111/wusa.12259
- Burstein, P. (2003). The impact of public opinion on public policy: A review and an agenda. Political Research Quarterly, 56(1), 29–40. https://doi.org/https://doi.org/10.1177/106591290305600103
- Charmaz, K. (2014). Constructing grounded theory/Kathy Charmaz (2nd ed.). SAGE Publications.
- Cleary, E. G., Beierlein, J. M., Khanuja, N. S., McNamee, L. M., & Ledley, F. D. (2018). Contribution of NIH funding to new drug approvals 2010–2016. Proceedings of the National Academy of Sciences, 115(10), 2329–2334. https://doi.org/https://doi.org/10.1073/pnas.1715368115
- DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016). Innovation in the pharmaceutical industry: New estimates of R&D costs. Journal of Health Economics, 47, 20–33. https://doi.org/https://doi.org/10.1016/j.jhealeco.2016.01.012
- Esmail, L. C., Phillips, K., Kuek, V., Cosio, A. P., & Kohler, J. C. (2010). Framing access to medicines in developing countries: An analysis of media coverage of Canada’s access to medicines regime. BMC International Health and Human Rights, 10(1), 1. https://doi.org/https://doi.org/10.1186/1472-698X-10-1
- Flynn, M. B. (2015). Pharmaceutical autonomy and public health in Latin America: State, society and industry in Brazil’s AIDS Program (1st ed.). Routledge.
- Flynn, M. B., & Silva, E. O. (2020). Criticizing and legitimizing patent monopolies: The struggle over hepatitis C medicines in Brazil’s digital universe. In M. Ellis (Ed.), Critical global semiotics: Understanding sustainable transformational citizenship. Routledge. https://www.crcpress.com/Critical-Global-Semiotics-Understanding-Sustainable-Transformational-Citizenship/Ellis/p/book/9780367076986.
- Fourcade, M., & Healy, K. (2007). Moral views of market society. Annual Review of Sociology, 33(1), 285–311. https://doi.org/https://doi.org/10.1146/annurev.soc.33.040406.131642
- Gauchat, G. (2012). Politicization of science in the public sphere: A study of public trust in the United States, 1974 to 2010. American Sociological Review, 77(2), 167–187. https://doi.org/https://doi.org/10.1177/0003122412438225
- Gaudette, T., Scrivens, R., Davies, G., & Frank, R. (2020). Upvoting extremism: Collective identity formation and the extreme right on Reddit. New Media & Society. https://doi.org/https://doi.org/10.1177/1461444820958123
- Gruskin, S., & Raad, Z. (2010). Are drug companies living up to their human rights responsibilities? Moving toward assessment. PLoS Medicine, 7(9), e1000310. https://doi.org/https://doi.org/10.1371/journal.pmed.1000310
- GTPI. (2020, November 13). GTPI pede anulação da patente do remdesivir. De olho nas patentes - Grupo de Trabalho sobre Propriedade Intelectual. http://deolhonaspatentes.org/gtpi-pede-anulacao-da-patente-do-remdesivir/.
- Hall, S. (1986). Gramsci’s relevance for the study of race and ethnicity. Journal of Communication Inquiry, 10(2), 5–27. https://doi.org/https://doi.org/10.1177/019685998601000202
- Hill, A., Wang, J., Levi, J., Heath, K., & Fortunak, J. (2020). Minimum costs to manufacture new treatments for COVID-19. Journal of Virus Eradication, 6(2), 61–69. https://doi.org/https://doi.org/10.1016/S2055-6640(20)30018-2
- Hogerzeil, H. V. (2006). Essential medicines and human rights: What can they learn from each other? Bulletin of the World Health Organization, 84(5), 371–375. https://doi.org/10.2471/blt.06.031153
- Jasper, J. (1997). The art of moral protest: Culture, biography, and creativity in social movements. University of Chicago Press.
- Jessop, B. (2004). Critical semiotic analysis and cultural political economy. Critical Discourse Studies, 1(2), 159–174. https://doi.org/https://doi.org/10.1080/17405900410001674506
- Kang, S.-Y., Bai, G., DiStefano, M. J., Socal, M. P., Yehia, F., & Anderson, G. F. (2020). Comparative approaches to drug pricing. Annual Review of Public Health, 41(1), 499–512. https://doi.org/https://doi.org/10.1146/annurev-publhealth-040119-094305
- Kapstein, E. B., & Busby, J. (2013). AIDS drugs for all. Cambridge University Press.
- KEI. (2020). KEI briefing note 2020:1 Role of the federal government in the development of GS-5734/Remdesivir. Knowledge Ecology International. https://www.keionline.org/BN-2020-1.
- King, B. G., & Pearce, N. A. (2010). The contentiousness of markets: Politics, social movements, and institutional change in markets. Annual Review of Sociology, 36(1), 249. https://doi.org/https://doi.org/10.1146/annurev.soc.012809.102606
- Laclau, E., & Mouffe, C. (1985). Hegemony and socialist strategy: Towards a radical democratic politics (2nd ed.). Verso.
- Lexchin, J. (2018). The pharmaceutical industry in contemporary capitalism. Monthly Review, 37–50. https://doi.org/https://doi.org/10.14452/MR-069-10-2018-03_3
- Light, D. W. (2008). Pricing pharmaceuticals in the USA. In Norman J. Temple, Andrew Thompson, & Anwar Khan (Eds.), Excessive medical spending (pp. 63–79). Radcliffe.
- Light, D. W. (2020). Addressing health care disparities: A radical perspective and proposal. Frontiers in Sociology, 5, https://doi.org/https://doi.org/10.3389/fsoc.2020.00029
- Light, D. W., & Maturo, A. F. (2015). Good pharma: The public-health model of the Mario Negri Institute. Palgrave Macmillan.
- Lofland, J., Snow, D. A., & Anderson, L. (2006). Analyzing social settings: A guide to qualitative observation and analysis (4th ed.). Wadsworth/Thomson Learning.
- Lupkin, S. (2020, June 29). Remdesivir priced at more than $3,100 for a course of treatment. NPR.Org. https://www.npr.org/sections/health-shots/2020/06/29/884648842/remdesivir-priced-at-more-than-3-100-for-a-course-of-treatment.
- McCarthy, J. (2019, September 3). Big pharma sinks to the bottom of U.S. industry rankings. Gallup.Com. https://news.gallup.com/poll/266060/big-pharma-sinks-bottom-industry-rankings.aspx.
- McDonnell, M.-H., King, B. G., & Soule, S. A. (2015). A dynamic process model of private politics: Activist targeting and corporate receptivity to social challenges. American Sociological Review, 80(3), 654. https://doi.org/https://doi.org/10.1177/0003122415581335
- Mirabito, A. M., Otnes, C. C., Crosby, E., Wooten, D. B., Machin, J. E., Pullig, C., Adkins, N. R., Dunnett, S., Hamilton, K., Thomas, K. D., Yeh, M. A., Davis, C., Gollnhofer, J. F., Grover, A., Matias, J., Mitchell, N. A., Ndichu, E. G., Sayarh, N., & Velagaleti, S. (2016). The stigma turbine: A theoretical framework for conceptualizing and contextualizing marketplace stigma. Journal of Public Policy & Marketing, 35(2), 170–184. https://doi.org/https://doi.org/10.1509/jppm.15.145
- MSF Access Campaign. (2020, March 30). Open letter: Civil society urges Gilead to take immediate action to ensure access to potential COVID-19 treatment. Médecins Sans Frontières Access Campaign. https://msfaccess.org/open-letter-civil-society-urges-gilead-take-immediate-action-ensure-access-potential-covid-19.
- Owen, T. (2014). The ‘access to medicines’ campaign vs. big pharma. Critical Discourse Studies, 11(3), 288–304. https://doi.org/https://doi.org/10.1080/17405904.2014.915860
- Ozawa, S., Shankar, R., Leopold, C., & Orubu, S. (2019). Access to medicines through health systems in low- and middle-income countries. Health Policy and Planning, 34(Supplement_3), iii1–iii3. https://doi.org/https://doi.org/10.1093/heapol/czz119
- Pimentel, J., Laurie, C., Cockcroft, A., & Andersson, N. (2020). Clinical studies assessing the efficacy, effectiveness, and safety of remdesivir in management of COVID-19: A scoping review. British Journal of Clinical Pharmacology. https://doi.org/https://doi.org/10.1111/bcp.14677
- Rocha, M. M., de Andrade, E. P., Alves, E. R., Cândido, J. C., & Borio, M. M. (2020). Access to innovative medicines by pharma companies: Sustainable initiatives for global health or useful advertisement? Global Public Health, 15(6), 777–789. https://doi.org/https://doi.org/10.1080/17441692.2020.1729391
- Sell, S. K., & Prakash, A. (2004). Using ideas strategically: The contest between business and NGO networks in intellectual property rights. International Studies Quarterly, 48(1), 143–175. https://doi.org/https://doi.org/10.1111/j.0020-8833.2004.00295.x
- Shadlen, K. C. (2017). Coalitions and compliance: The political economy of pharmaceutical patents in Latin America. Oxford University Press.
- Sheahan, T. P., Sims, A. C., Graham, R. L., Menachery, V. D., Gralinski, L. E., Case, J. B., Leist, S. R., Pyrc, K., Feng, J. Y., Trantcheva, I., Bannister, R., Park, Y., Babusis, D., Clarke, M. O., Mackman, R. L., Spahn, J. E., Palmiotti, C. A., Siegel, D., Ray, A. S., … Baric, R. S. (2017). Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Science Translational Medicine, 9(396), 396. https://doi.org/https://doi.org/10.1126/scitranslmed.aal3653
- Silverman, E. (2020, May 12). Gilead signs deals for generic companies to make and sell remdesivir. STAT. https://www.statnews.com/pharmalot/2020/05/12/gilead-generics-remdesivir-covid19-coronavirus-licenses/.
- Snow, D. A. (2008). Elaborating the discursive contexts of framing: Discursive fields and spaces. In N. K. Denzin (Ed.), Studies in Symbolic Interaction (Vol. 30, pp. 3–28). Emerald Group Publishing Limited. https://doi.org/https://doi.org/10.1016/S0163-2396(08)30001-5
- Snow, David, Rochford, E. Burke, Worden, Steven, & Benford, Robert. (1986). Frame alignment processes, micromobilization and movement participation. American Sociological Review, 51, 464–481. https://doi.org/10.2307/2095581
- Son, K.-B., & Lee, T.-J. (2018). Compulsory licensing of pharmaceuticals reconsidered: Current situation and implications for access to medicines. Global Public Health, 13(10), 1430–1440. https://doi.org/https://doi.org/10.1080/17441692.2017.1407811
- Stavinoha, L. (2016). Losing the media battle, waging the policy war: The pharmaceutical industry’s response to the access to medicines crisis in the global south. Global Media and Communication, 12(3), 275–294. https://doi.org/https://doi.org/10.1177/1742766516676206
- Stolberg, S. G. (2020, September 13). Trump issues expansive order aimed at lowering drug prices. The New York Times. https://www.nytimes.com/2020/09/13/us/politics/trump-executive-order-drug-prices.html.
- Walker, J. (2020, June 29). Covid-19 drug Remdesivir to cost $3,120 for typical patient. Wall Street Journal. https://www.wsj.com/articles/covid-19-drug-remdesivir-to-cost-3-120-for-typical-patient-11593428402.
- WHO. (2020, November 20). WHO recommends against the use of remdesivir in COVID-19 patients. World Health Organization. https://www.who.int/news-room/feature-stories/detail/who-recommends-against-the-use-of-remdesivir-in-covid-19-patients.
- Wouters, O. J., McKee, M., & Luyten, J. (2020). Estimated research and development investment needed to bring a new medicine to market, 2009-2018. JAMA, 323(9), 844–853. https://doi.org/https://doi.org/10.1001/jama.2020.1166
- Young, M. (2006). Bearing witness against sin: The evangelical birth of the American social movement. University of Chicago Press.